Noveome Biotherapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

noveome.com

Founded Year

2000

Stage

Unattributed | Alive

Total Raised

$23.78M

Last Raised

$870K | 2 yrs ago

About Noveome Biotherapeutics

Noveome Biotherapeutics is regenerative medicine company focused on the research, development and clinical use of its technology platform, derived from human placental cells. This platform provides a new approach to tissue regeneration and repair in a wide range of medical conditions. Noveome's technology platform is derived from a population of cells isolated from full-term placental tissue that is normally discarded following delivery of a baby. There is no interruption in the development of the baby to procure this tissue.

Noveome Biotherapeutics Headquarter Location

100 Technology Drive

Pittsburgh, Pennsylvania, 15219,

United States

412-402-9914

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Noveome Biotherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Noveome Biotherapeutics is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Noveome Biotherapeutics Patents

Noveome Biotherapeutics has filed 24 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Inflammations
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/25/2017

5/14/2019

Neurotrauma, Neurological disorders, Rare diseases, Transcription factors, Syndromes

Grant

Application Date

4/25/2017

Grant Date

5/14/2019

Title

Related Topics

Neurotrauma, Neurological disorders, Rare diseases, Transcription factors, Syndromes

Status

Grant

Latest Noveome Biotherapeutics News

Persistent Corneal Epithelial Defects Therapeutics Market Size Anticipated to Boost at a CAGR of 18.69% for the Study Period 2018-2030 | DelveInsight

Oct 12, 2021

| DelveInsight The Persistent Corneal Epithelial Defects pipeline therapies expected to get launched in the forecasted period include Nexagon, ST266, RGN-259, REC-0559, and others. These are expected to create a positive shift in the Persistent Corneal Epithelial Defects market during the forecast period (2021-2030). News provided by Share this article Share this article LAS VEGAS, Oct. 12, 2021 /PRNewswire/ -- DelveInsight's Persistent Corneal Epithelial Defects (PEDs or PCEDs) Market  report offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). As per DelveInsight's estimate, the total Persistent Corneal Epithelial Defects incident cases in 2020 were reported to be 241,452 in the 7MM. DelveInsight estimates that PCED affects males more as compared to females. The PCED therapy market space is monopolized by aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. The Persistent Corneal Epithelial Defects therapeutic market size appears to be dominated by the United States in 2020, worth USD 83.9 million. Key pharmaceutical and biotech companies actively engaged in the Persistent Corneal Epithelial Defects market space include OcuNexus Therapeutics, Eyevance Pharmaceuticals, and Noveome Biotherapeutics, among others. The Persistent Corneal Epithelial Defects pipeline therapies expected to launch in the forecasted period (2021-2030) include Nexagon, ST266, RGN-259, REC-0559, and others. The anticipated launch of the pipeline therapies is expected to create a positive shift in the market during the forecast period (2021-2030). Nexagon (OcuNexus Therapeutics, Eyevance Pharmaceuticals) is a first-in-class natural, antisense therapy that downregulates the cell membrane hemichannel forming protein, connexin43 (Cx43). The demand for novel therapies with the absence of key players led to the boosted R&D from the academic-industry partnership that led to the prompting of open innovation and prioritizing the targeting of PED. Novel therapies being investigated recently are beginning to show promise in the treatment of the nonhealing corneal epithelium. Download Persistent Corneal Epithelial Defects Market Snapshot report to understand which Persistent Corneal Epithelial Defects drug is going to capture the maximum market share @  Persistent Corneal Epithelial Defects Therapy Market Analysis and Forecast  Persistent Corneal Epithelial Defects: Disease Overview Persistent Corneal Epithelial Defects (PCED/ PED) are characterized by the failure of the rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Persistent Corneal Epithelial Defects Epidemiological Segmentation DelveInsight's Persistent Corneal Epithelial Defects Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into: Total  Persistent Corneal Epithelial Defects Incident Cases  Gender-specific PCED Incidence  Etiology-specific  Persistent Corneal Epithelial Defects Incidence  Understand how Persistent Corneal Epithelial Defects Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Persistent Corneal Epithelial Defects Epidemiology Market Report Summary The current approaches include aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. Membrane grafting, autologous serum, scleral contact lenses, and others are available for relapse cases. Persistent epithelial defects of the cornea can be challenging to even the experienced ophthalmologist. Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is essential to treat the underlying causative condition, including infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. In individuals with PCEDs, there is a high risk of infection or further injury resulting in permanent vision loss due to corneal scarring, infection, neovascularization, and incomplete wound healing. The current PCED therapy market has several unmet needs in the form of a lack of adequate and curative therapies that can heal or reverse the damage to the cornea. Several pharmaceutical and biotech companies such as OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and several others are working to keep the market growth steady, showcasing an encouraging future picture. DelveInsight estimates that with an entry of pharmaceutical pharma players and the expected launch of novel therapies, the futuristic outlook of the PCED market is anticipated to be promising during the next decade. Besides, a better understanding of the condition of increased healthcare expenditure and funding from international organizations shall further add to the growth of the Persistent Corneal Epithelial Defects market share. Persistent Corneal Epithelial Defects Pipeline Therapies in focus in the report analysis Nexagon: OcuNexus Therapeutics Persistent Corneal Epithelial Defects Market Dynamics Persistent Corneal Epithelial Defects Market to grow due to rising prevalence and increased awareness about the PED and its association with other diseases and its detection. Identifying potential targets, orphan designations, market exclusivity, support from various organizations are attracting the companies to develop novel therapies, which may increase the future Persistent Corneal Epithelial Defects market growth. Nevertheless, the growth of the Persistent Corneal Epithelial Defects Market may be hindered by the poor response rate and various side effects of the available treatment option. Also, stringent regulatory procedures by regulatory authorities on medication and devices are hampering the persistent epithelial defects treatments market.

Noveome Biotherapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Noveome Biotherapeutics Rank

  • When was Noveome Biotherapeutics founded?

    Noveome Biotherapeutics was founded in 2000.

  • Where is Noveome Biotherapeutics's headquarters?

    Noveome Biotherapeutics's headquarters is located at 100 Technology Drive, Pittsburgh.

  • What is Noveome Biotherapeutics's latest funding round?

    Noveome Biotherapeutics's latest funding round is Unattributed.

  • How much did Noveome Biotherapeutics raise?

    Noveome Biotherapeutics raised a total of $23.78M.

  • Who are Noveome Biotherapeutics's competitors?

    Competitors of Noveome Biotherapeutics include Animal Cell Therapies, Vitatex, NGM Biopharmaceuticals, Aerie Pharmaceuticals, Amicus Therapeutics, Hemarina, RhinoCyte, Merrimack Pharmaceuticals, VirxSys, Garnet BioTherapeutics and 16 more.

You May Also Like

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

M
Minerva Biotechnologies

Minerva Biotechnologies developd biochips: nanoparticles coated with functionalized affinity surfaces. Minerva has developed user-friendly nanoparticles that the end user can utilize as a "black box technology". The nanoparticle system can be fully automated and a range of nanoparticles have been developed so that the readout is compatible with existing lab equipment.

R
Receptor Logic

Receptor Logic is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T-Cell Receptors in the immune system. These T-Cell Receptor mimics (TCRms) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. For more information, visit the company website www.receptorlogic.com.About Emergent Technologies, Inc.Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region.

A
Animal Cell Therapies

Animal Cell Therapies is a biotech firm that aims to improve the lives of animals through thoughtful research and development. The ACT team is focused on developing and delivering cellular treatment and services to customers.

Cell Line Genetics Logo
Cell Line Genetics

Cell Line Genetics aims to provide services and products to support research institutions, as well as biotechnology and pharmaceutical companies focused on embryonic stem cell and cancer research.

D
Digna Biotech

Digna Biotech is a biotechnological company dedicated to the development and exploitation of the research products generated by the Center of Applied Medical Research (Centro de Investigación M©dica Aplicada, CIMA) in Pamplona. The goal of the company is to lead the development of preclinical studies and clinical trials originating from intellectual property generated by its investigators. CIMA is an important private biomedical research center, with more than 300 researchers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.